For its fourth fiscal quarter (ending December 31), Neurocrine Biosciences Inc (NASDAQ: NBIX) has reported a -31% decline in E.P.S. from $1.50 a year ago to $1.03 in the current quarter. E.P.S. were $3.40 for the latest four quarters through December 31 versus $2.56 for the same period a year ago — an increase of 33%.
Recent Price Action
On 2/6/25, Neurocrine Biosciences Inc (NASDAQ: NBIX) stock declined slightly by -0.5%, closing at $150.51. Moreover, this decline was accompanied by above average trading volume at 134% of normal. The stock has performed in line with the market over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
Neurocrine Biosciences has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Neurocrine Biosciences has a neutral Appreciation Score of 49 and a slightly negative Power Rating of 31, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment